In this episode, we dive into a recent open-label randomized controlled trial on the adjuvant use of midodrine in patients with septic shock. Researchers investigated whether adding midodrine to norepinephrine therapy could improve survival rates.
The findings? Midodrine reduced the need for vasopressors, but did not significantly lower 28-day in-hospital mortality or shorten hospital stays. While midodrine showed some impact on reducing vasopressor requirements, its effect on overall outcomes remains limited.
Tune in for a quick breakdown of what this means for ICU practice and managing septic shock patients.
ResusX:Podcast